Drugs in clinical use that are nephroprotective and can reduce renal fibrosis in both humans and experimental animal models of CKD include the renin-angiotensin blockers, mineralocorticoid receptor (MR) antagonists, and sodium/glucose cotransporter 2 inhibitors (SGLT2i). This evidence concerns the gene SLC5A2 and chronic kidney disease.